Previous Article | Next Article 
Mol Cell Biol, May 1998, p. 2486-2491, Vol. 18, No. 5
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Activation of the Small GTPase Ral in
Platelets
Rob M. F.
Wolthuis,1
Barbara
Franke,1,2
Miranda
van Triest,1,2
Bettina
Bauer,3
Robbert H.
Cool,3
Jacques H.
Camonis,4
Jan-Willem N.
Akkerman,2 and
Johannes L.
Bos1,*
Laboratory for Physiological
Chemistry1 and
Department of
Hematology,2 Utrecht University, 3584 CG
Utrecht, The Netherlands;
Abteilung Strukturelle Biologie,
Max-Planck-Institut für Molekulare Physiologie, 44139 Dortmund, Germany3; and
U248 INSERM,
Section de Recherche, Institut Curie, 75248 Paris Cedex 05, France4
Received 7 November 1997/Returned for modification 18 December
1997/Accepted 1 February 1998
 |
ABSTRACT |
Ral is a ubiquitously expressed Ras-like small GTPase which is
abundantly present in human platelets. The biological function of Ral
and the signaling pathway in which Ral is involved are largely unknown.
Here we describe a novel method to measure Ral activation utilizing the
Ral binding domain of the putative Ral effector RLIP76 as an
activation-specific probe. With this assay we investigated the
signaling pathway that leads to Ral activation in human platelets. We
found that Ral is rapidly activated after stimulation with various
platelet agonists, including
-thrombin. In contrast, the platelet
antagonist prostaglandin I2 inhibited
-thrombin-induced
Ral activation. Activation of Ral by
-thrombin could be inhibited by
depletion of intracellular Ca2+, whereas the induction of
intracellular Ca2+ resulted in the activation of Ral. Our
results show that Ral can be activated by extracellular stimuli.
Furthermore, we show that increased levels of intracellular
Ca2+ are sufficient for Ral activation in platelets. This
activation mechanism correlates with the activation mechanism of the
small GTPase Rap1, a putative upstream regulator of Ral guanine
nucleotide exchange factors.
 |
INTRODUCTION |
RalA and RalB are very similar small
GTPases that have 55% sequence identity with Ras (6, 7,
41). Ral and Ras have comparable nucleotide binding
characteristics and low intrinsic GTPase activity (19). The
Ral proteins are ubiquitously expressed but are particularly abundant
in brain, testes, and platelets (2, 21, 39). Ral becomes
posttranslationally processed and is found in the plasma membrane
(16) as well as in endocytotic vesicles (41) or
synaptic vesicles (50). In platelets, Ral is a major GTP
binding protein that is present in the plasma membrane and specifically
in dense granules, a class of secretory organelles (29, 41).
Recently, a putative effector protein of RalA and RalB has been
identified; it has been designated RLIP76 but is also termed RalBP1 or
RIP1 (5, 22, 40). RLIP76 interacts with the active, GTP-bound form of Ral, both in the yeast two-hybrid system and in
vitro. Interaction studies using the yeast two-hybrid system and
deletion mutants of RLIP76 demonstrate that the Ral binding region is
located in the C-terminal region, between amino acids 403 and 499 (22). Interestingly, RLIP76 exhibits GTPase-activating protein (GAP) activity for the Rho-like GTPase Cdc42, suggesting that
Ral may be involved in the regulation of Cdc42 (5, 22, 40).
Cdc42 plays a role in the organization of the actin cytoskeleton and
the regulation of cytoskeletal polarity.
Ral also interacts with phospholipase D1 (PLD1) (21, 28).
The interaction between Ral and PLD1 is independent of the nucleotide binding of Ral and occurs via the N-terminal region of Ral (21, 28). In platelets and other cells, PLD has been implicated in vesicle transport, regulation of the actin cytoskeleton, and generation of lysophosphatidic acid, which is secreted by platelets upon activation (14, 31).
Different proteins that regulate the activity of Ral have been
identified. A RalGAP with a high molecular mass was purified from brain
and testes, whereas a 34-kDa RalGAP was found in human platelets
(3, 13). Furthermore, several Ral guanine nucleotide exchange factors (RalGEFs) have been cloned (1, 10, 34, 52).
Three of these RalGEFs, RalGDS, Rgl, and Rlf, can bind to and become
activated by Ras via their C-terminally located Ras binding domains
both in vitro and in vivo, indicating that RalGEFs function as Ras
effector proteins (34, 48, 53). Apart from Ras, the
activated versions of other members of the Ras family of proteins,
Rap1, Rap2, R-Ras, and TC21, can interact with RalGEFs (27, 44,
48, 52). These might thus be involved in the activation of Ral as
well, although cotransfection experiments with Cos7 cells suggested
that Rap1 and R-Ras cannot activate RalGDS (48). However,
the lack of information about the physiological activation of Ral by
extracellular stimuli has been an obstacle to further understanding the
regulation and function of Ral. The unavailability of antibodies
suitable for efficient immunoprecipitation and subsequent analysis of
bound nucleotides has so far precluded the analysis of growth
factor-induced Ral activation.
In this report we present an alternative assay for the detection of
endogenously activated Ral. We used the Ral binding domain (RalBD) of
RLIP76, which interacts specifically with the GTP-bound form of Ral, to
monitor the activity of Ral in human platelets, and we show that
-thrombin and other platelet agonists stimulate a rapid and strong
activation of Ral. We demonstrate that the elevation of
Ca2+ levels is involved in the activation of Ral. Finally,
we discuss the stimulus-induced activations of Ras, Rap1, and Ral.
 |
MATERIALS AND METHODS |
Isolation of GST-RalBD.
Glutathione S-transferase
(GST)-RalBD containing amino acids 397 to 518 of human RLIP76
(22) was cloned into pGEX4T3 by PCR with specific primers
introducing a BamHI and a XhoI site. AD202
protease-negative bacteria were transformed with the pGEX4T3-GST-RalBD construct. GST-RalBD was isolated from
isopropyl-
-D-thiogalactopyranoside (IPTG)-induced
bacteria as described for GST-Rlf (53). Purified protein was
concentrated and was stored in a solution containing 10% glycerol, 50 mM Tris (pH 7.4), 150 mM NaCl, 5 mM MgCl2, and 5 mM
dithioerythritol (DTE) at
70°C.
Determination of Ral-GTP levels.
Cos7 cells were cultured in
100-mm dishes in Dulbecco's modified Eagle medium-10% fetal calf
serum-0.05% glutamine and tranfected with 3 µg of pMT2 expression
vectors encoding hemagglutinin (HA)-Ral, HA-RalV23, or HA-RalN28, as
described previously (53). For determination of levels of
GTP bound to Ral, transfected Cos7 cells were put in 1.5% serum
overnight and subsequently metabolically labeled with 150 µCi of
32Pi for 5 h in phosphate-free medium.
Next, cells were lysed, transfected Ral proteins were recovered in
12CA5 immunoprecipitations, bound nucleotides were eluted and
separated, and GTP/GDP ratios were determined with a PhosphorImager, as
described previously (53).
Platelets.
Platelets were prepared as described previously
(18) and resuspended in HEPES/Tyrode buffer at 3 × 108 platelets/ml. Platelets were left at room temperature
for 30 min. Samples of 1.0 ml were used for each point. Stimulation
with agonists at 37°C was performed without stirring. Prior to
ionomycin treatment, 1 mM CaCl2 was added to the platelet
suspension.
Use of RalBD as an activation-specific probe.
Platelets were
lysed (2:1, vol/vol) in 3× Ral buffer (final concentrations: 10%
glycerol, 1% Nonidet P-40, 50 mM Tris-HCl [pH 7.4], 200 mM NaCl, 2.5 mM MgCl2, 1 mM phenylmethylsulfonyl fluoride, 1 µM
leupeptin, 10 µg of soybean trypsin inhibitor per ml, and 0.1 µM
aprotinin). Lysates were clarified by centrifugation and the
supernatants of each sample were incubated with 15 µg of GST-RalBD
precoupled to glutathione beads. Samples were incubated for 1 h on
a tumbler at 4°C. Beads were washed four times in Ral buffer.
Remaining fluid was removed with an insulin syringe, and beads were
collected in Laemmli sample buffer. As a control, Ral levels in whole
lysates were determined. Samples were analyzed by sodium dodecyl
sulfate (SDS)-polyacrylamide gel electrophoresis (SDS-PAGE) (12.5%
polyacrylamide) and Western blotting with a monoclonal anti-RalA
antibody (Transduction Laboratories).
For in vitro analysis, 800 µg of GST-RalBD was bound to 700 µl of
glutathione-Sepharose beads (Pharmacia) in 8 ml of a solution of 15%
glycerol, 1% Nonidet P-40, 50 mM Tris-HCl (pH 7.5), 100 mM NaCl, 2 mM
MgCl2, 1 mM phenylmethylsulfonyl fluoride, and 25 nM
Pefablock. Beads were collected by centrifugation and washed in the
same buffer. A 4 µM concentration of a C-terminally truncated version
of simian RalA (sRalA, representing amino acids 1 to 178) isolated from
Escherichia coli was loaded with GDP or Gpp(NH)p and
incubated with 3 µM GST-RalBD bound to glutathione beads for 1 h
at 4°C. Beads were collected and washed three times with the same
buffer and resuspended in 80 µl of Laemmli sample buffer. Ten
microliters of the sample was separated by SDS-12.5% PAGE and protein
was detected by Coomassie brilliant blue staining.
Ras and Rap1 activation assays.
The GTP-bound forms of Ras
and Rap1 were specifically pulled down from clarified platelet lysates
by incubation with the GST-tagged forms of the Raf1-Ras binding domain
(RBD) or RalGDS-RBD, respectively, precoupled to glutathione beads, as
described previously (12, 18). However, we used the Ral
buffer indicated above for cellular lysis and washing of the beads
since this resulted in a higher sensitivity without affecting the
specificity (data not shown). In the experiments in which the different
small GTPases were compared, the lysates were split and used for the
determination of either Ras, Rap1, or Ral activity.
 |
RESULTS |
The RalBD of RLIP76 interacts specifically with RalGTP.
Based
on structural predictions of the coiled-coil region encompassing the
Ral binding region of RLIP76, we used a GST fusion protein containing
amino acids 397 to 518 of RLIP76 that was predicted to be sufficient
for direct interaction with Ral in vitro (GST-RalBD) (Fig.
1A). To investigate its interaction with
Ral, GST-RalBD was incubated with purified sRalA (C-terminally
truncated) that was bound to either GDP or a nonhydrolyzable GTP
analog, Gpp(NH)p, at 4°C. Subsequently, GST-RalBD was pulled down on
glutathione beads, the beads were washed, and bound proteins were
analyzed by SDS-PAGE and gel staining. Figure 1B shows that GST-RalBD
interacts with sRalA-Gpp(NH)p and not with sRalA-GDP.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
A GST fusion protein of the RalBD of RLIP76 binds
specifically to the activated form of Ral. (A) Schematic representation
of RLIP76, indicating the position of the RalBD of RLIP76 that was used
to generate the GST-RalBD. (B) In vitro analysis of the interaction
between GST-RalBD and sRalA. A 3µM concentration of GST-RalBD was
precoupled to glutathione-Sepharose beads and washed. A 4 µM
concentration of a C-terminally truncated sRalA loaded with GDP or
Gpp(NH)p (a nonhydrolyzable GTP analog) was incubated with the
precoupled beads. After 1 h of incubation at 4°C, beads were
washed three times and resuspended in 80 µl of sample buffer, of
which 10 µl was loaded onto an SDS-PAGE gel. After separation, the
proteins were stained by Coomassie brilliant blue. The numbers are
molecular masses of the marker proteins, in kilodaltons. (C) Analysis
of GTP levels of HA-Ral mutants by different methods. The left panel
shows the percentage of GTP bound to ectopically expressed wild-type
HA-Ral (HA-Ral-WT), activated HA-Ral (HA-RalV23), and inactive HA-Ral
(HA-RalN28) in serum-starved Cos7 cells. Error bars indicate the
variations between two independent experiments. The right panel shows
the detection of HA-RalGTP in a GST-RalBD pull-down experiment.
Therefore, the transfected Cos7 cells were serum starved, lysed, and
incubated with 15 µg of GST-RalBD precoupled to glutathione beads to
recover GTP-bound Ral. Beads were washed four times, and collected Ral
was identified by Western analysis with an anti-HA (12CA5) monoclonal
antibody (lanes 4 to 6). The first three lanes show the levels of the
transfected HA-Ral mutants in the whole lysates. In these lanes, 5% of
the lysate used for the pull-down experiment was loaded onto the gel.
|
|
In order to further evaluate the use of this method, we transfected
Cos7 cells with epitope-tagged versions of wild-type Ral
or active
(RalV23) or inactive (RalN28) mutants. First, the GTP
levels of the
different mutants were determined after labeling
of the cells with
[
32P]orthophosphate. The left panel of Fig.
1C shows that
after serum
starvation, wild-type Ral contained approximately 8% GTP,
while
more than 85% of the HA-RalV23 molecules were GTP bound, in
contrast
to HA-RalN28, which was almost exclusively bound to GDP. In a
parallel experiment, we used GST-RalBD to pull down HA-RalGTP
from the
lysates of the transfected cells. The right panel of
Fig.
1C shows that
the relative amounts of HA-Ral isolated from
Cos7 cells as detected by
immunoblotting correlated well with
the GTP levels of the expressed Ral
proteins. Together with the
in vitro data, this shows that GST-RalBD
specifically interacts
with RalGTP and can be used to monitor Ral
activation in cells.
-Thrombin and platelet agonists induce rapid activation of
Ral.
Human platelets were treated with 0.1 U of
-thrombin per
ml, which induces complete aggregation of stirred platelets within 5 to
10 min (49), for different periods of time. RalGTP was pulled down from the cell lysates by GST-RalBD precoupled to
glutathione beads. Subsequently, the amount of RalGTP was analyzed by
Western blotting with a monoclonal anti-RalA antibody, which recognizes RalA as a single 27-kDa protein and which does not cross-react with Ras
or Rap1 (data not shown). Due to the very high homology between RalA
and RalB, RalB may be recognized as well.
Figure
2A shows that, whereas in resting
platelets hardly any RalGTP was found, stimulation with 0.1 U of

-thrombin per ml
induced a rapid increase in the amount of RalGTP
collected by
GST-RalBD. The activation of Ral was maximal after 1 min
of

-thrombin
stimulation but remained elevated for at least 10 min.
In order
to estimate the increase of Ral activation by

-thrombin, a
range
of dilutions of the RalGTP precipitated by GST-RalBD from
stimulated
platelets was made and compared with RalGTP isolated from
resting
platelets. The signal obtained from a 6- to 10-fold dilution
approximated
that from RalGTP isolated from resting platelets (Fig.
2B), indicating
that treatment of the platelets with 0.1 U of

-thrombin per ml
stimulates Ral activation at least 6-fold.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 2.
Stimulation of platelets with -thrombin ( -thr) and
other platelet agonists leads to rapid activation of Ral. (A)
Activation of Ral by -thrombin. Human platelets were isolated as
described previously (18) and stimulated with 0.1 U of
-thrombin per ml for different times. The platelets were lysed and
incubated with 15 µg of GST-RalBD precoupled to glutathione beads to
recover GTP-bound Ral. Beads were washed four times, and collected Ral
was identified by Western analysis with a monoclonal anti-RalA antibody
(upper panel). The lower panel shows the levels of Ral in the whole
lysates. (B) Determination of RalGTP induction. Platelets were
stimulated with -thrombin for 1 min and Ral activation was
determined as described for panel A. In order to estimate the increase
in RalGTP induced by -thrombin, the -thrombin-induced sample (far
left) was diluted severalfold so it could be compared to the resting
platelets (--). The gel shows that the signal obtained after a
6- to 10-fold dilution of the RalGTP obtained from
-thrombin-stimulated platelets matches the amount of Ral detected in
resting platelets. (C) Ral activation by different platelet agonists.
Platelets were stimulated for 1 and 3 min with 0.1 U of -thrombin
per ml, thrombin receptor-activating peptide (TRAP, 10 µM), PAF (200 nM), TxA2 analog U46619 (1 µM), or ADP (10 µM). Ral
activation was analyzed as described for panel A. (D) Ral activation
occurs independently of TxA2 formation. Platelets were
treated with 30 µM indomethacin for 10 min to inhibit
TxA2 formation, prior to stimulation with 0.1 U of
-thrombin per ml for the indicated times, or were stimulated with
0.1 U of -thrombin per ml alone. At the concentration used,
indomethacin inhibits TxA2 formation (not shown).
Activation of Ral was monitored as described for panel A.
|
|
The thrombin receptor-activating peptide, which mimics

-thrombin by
binding to and activating the thrombin receptor, also
activates Ral
(Fig.
2C). We investigated the effects of other
platelet agonists on
Ral activation. We observed that platelet-activating
factor (PAF) was
able to induce a rapid activation of Ral, although
this activation was
more transient than

-thrombin stimulation
(Fig.
2C). As a result of

-thrombin treatment, thromboxane A
2 (TxA
2),
a product of the cyclooxygenase-dependent arachidonic
acid pathway, is
formed and released and ADP is secreted from
vesicles. These agents act
in positive-feedback loops to platelet
activation (
43). ADP
did not activate Ral significantly, if
at all (Fig.
2C), but treatment
of platelets with the TxA
2 mimetic
U46619 did induce Ral
activation (Fig.
2C). Pretreatment with
the cyclooxygenase inhibitor
indomethacin did not significantly
inhibit

-thrombin-induced Ral
activation, demonstrating that

-thrombin-induced Ral activation is
not dependent on the release
of TxA
2 (Fig.
2D). Taken
together, these findings demonstrate
that different platelet agonists
stimulate a rapid activation
of Ral.
-Thrombin-induced Ral activation is inhibited by
PGI2.
Platelet activation is antagonized by agents
that stimulate the cyclic AMP/protein kinase A pathway (26),
such as prostaglandin I2 (PGI2). To further
investigate the importance of Ral activation in platelets, we tested
the effect of PGI2 on
-thrombin-induced Ral activation.
Figure 3 demonstrates that the addition
of 20 ng of PGI2 per ml prior to
-thrombin treatment was
sufficient to almost completely block
-thrombin-induced Ral
activation. PGI2 treatment did not affect the total protein
levels of Ral in the lysate (data not shown). Since Ral is activated by
agents that lead to the activation of platelets and blocked by a
platelet antagonist, our data suggest a stimulatory role for Ral in
platelet activation.

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 3.
Platelet antagonist PGI2 inhibits
-thrombin-induced activation of Ral. Platelets were treated with 20 ng of PGI2 per ml for 2 min prior to stimulation with 0.1 U
of -thrombin ( -thr) per ml or were stimulated with 0.1 U of
-thrombin per ml alone. Ral activation was analyzed as described in
the legend to Fig. 2. --, resting platelets.
|
|
-Thrombin-induced Ral activation involves Ca2+ but
not PKC.
The thrombin receptor in platelets may couple to
Gi, which inhibits adenylate cyclase, and to
Gq, which induces phosphoinositide hydrolysis leading to
diacylglycerol (DAG) generation and inositoltrisphosphate (InsP3) formation. DAG stimulates the protein kinase C
(PKC) pathway, whereas InsP3 releases Ca2+ from
the intracellular stores (43). In order to dissect the mechanism of
-thrombin-induced Ral activation, we examined whether PKC or increases in intracellular Ca2+ were involved in the
activation of Ral. First, platelets were treated with phorbol myristate
acetate (PMA) to activate PKC. PMA treatment did not result in the
rapid activation of Ral (Fig. 4A). To
test whether inhibition of PKC affects
-thrombin-induced Ral
activation, we used the PKC inhibitor bisindolylmaleimide (47). At concentrations at which either bisindolylmaleimide or staurosporine inhibited
-thrombin-induced aggregation of the platelets completely (data not shown), neither inhibited
-thrombin-induced Ral activation (Fig. 4B). These observations
indicate that
-thrombin-induced Ral activation is not mediated by
PKC.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
PKC is not involved in -thrombin-induced Ral
activation. (A) PKC activation does not lead to rapid Ral activation.
Platelets were stimulated with PMA (10 nM) for 1 and 3 min. (B)
Inhibition of PKC does not block -thrombin-induced Ral activation.
Platelets were treated with the PKC inhibitor bisindolylmaleimide (B, 5 µM, 1 min) or the kinase inhibitor staurosporine (S, 1 µM, 5 min)
prior to stimulation with 0.1 U of -thrombin ( -thr) per ml for 1 min or were stimulated with -thrombin alone. Ral activation was
analyzed as described in the legend to Fig. 2. --, resting
platelets. ctrl, control.
|
|
Next we examined whether an increase in the intracellular concentration
of Ca
2+ is involved in the activation of Ral. Pretreatment
with the intracellular
Ca
2+ chelator BAPTA-AM
[1,2-bis(
o-aminophenoxy)ethane-
N-N-N'-
N'-tetraacetate]
(
11) completely blocked

-thrombin-induced Ral activation,
suggesting
that the elevation of intracellular Ca
2+ levels
is the signal by which

-thrombin stimulates Ral activation
(Fig.
5A). In addition, treatment with agents
that induce an elevation
of Ca
2+, by stimulating either a
Ca
2+ influx (ionomycin) or a release from intracellular
Ca
2+ stores (thapsigargin), induced a rapid activation of
Ral (Fig.
5B). Indomethacin pretreatment (30 µM, 10 min) did not
block the
effect of ionomycin or thapsigargin on Ral, demonstrating
that
the formation of TxA
2 is not necessary for
Ca
2+-induced Ral activation (data not shown). Therefore, we
conclude
that

-thrombin-induced activation of Ral is mediated by an
increase
in intracellular Ca
2+ and that elevation of
intracellular Ca
2+ levels is sufficient to induce Ral
activation.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 5.
Ca2+ is necessary and sufficient for
activation of Ral. (A) Ca2+ is necessary for Ral activation
by -thrombin. Platelets preincubated or not for 30 min with 30 µM
BAPTA-AM, a chelator of intracellular Ca2+, were stimulated
with 0.1 U of -thrombin ( -thr) per ml for the indicated times.
Dimethyl sulfoxide (D) alone did not have an effect on Ral activation.
Analysis of Ral in total lysates demonstrated that BAPTA-AM did not
induce degradation of Ral (data not shown). (B) Ca2+ is
sufficient to induce Ral activation. Platelets were treated for the
indicated times with 100 nM ionomycin (iono) (in the presence of 1 mM
CaCl2 in the buffer) to promote Ca2+ influx or
with 100 nM thapsigargin (thap) to induce the release of
Ca2+ from intracellular stores. Ral activation was analyzed
as described in the legend to Fig. 2. --, resting platelets.
|
|
Ca2+-induced Ral activation is inhibited by
PGI2 and correlates with Rap1 activation.
Recently, we
and others have demonstrated that the formation of RalGTP can be
triggered by oncogenic Ras via the activation of RalGEFs (38, 48,
53). Apart from Ras, the RalGEFs can interact with the active
form of Rap1 both in vitro and in vivo (references 23,
44, and 52 and unpublished observations). Rap1, whose function is still elusive, is highly abundant in platelets (46) and becomes rapidly activated after
-thrombin
stimulation. Interestingly, for the activation of both Rap1 and Ral,
elevated levels of Ca2+ are both necessary and sufficient
(18). In addition, the activation of Rap1 by either
-thrombin or ionomycin is sensitive to PGI2 treatment.
Therefore, we compared the pattern of Ral activation with those of Ras
and Rap1 in platelets, using the previously described
activation-specific probes GST-Raf1-RBD and GST-RalGDS-RBD to monitor
the formation of RasGTP and Rap1GTP, respectively (12, 18).
-Thrombin stimulation led to the activation of Ral, Rap1, and Ras
with similar kinetics and this activation was blocked by
PGI2 pretreatment (Fig. 6A).
In contrast, when we measured ionomycin-induced activation of the three
GTPases, we found that both Ral and Rap1, but not Ras, were activated
in a PGI2-sensitive manner (Fig. 6B). This result shows
that in platelets, Rap1 and Ral, but not Ras, are coregulated by a
Ca2+-induced, PGI2-sensitive signaling pathway.

View larger version (37K):
[in this window]
[in a new window]
|
FIG. 6.
Ral activation by Ca2+ correlates with the
activation of Rap1 but not Ras. (A) -Thrombin-induced Ral activation
correlates with Rap1 and Ras activation. Platelets preincubated or not
for 2 min with 20 ng of PGI2 per ml were stimulated with
0.1 U of -thrombin ( -thr) per ml for the indicated times. Cell
lysates were split and analyzed for the presence of RalGTP, RasGTP, and
Rap1GTP. Ral activation (upper panel) was analyzed as described in the
legend to Fig. 2. Rap1GTP was isolated with GST-RalGDS-RBD precoupled
to glutathione beads and Western blotted with polyclonal anti-Rap1
(middle panel). The lower panel shows Ras activation. RasGTP was
isolated with GST-Raf1-RBD, precoupled to glutathione beads, and
analyzed by Western blotting with an anti-Ras monoclonal antibody
(Transduction Laboratories). These methods for the detection of Ras and
Rap1 activation have been described previously (12, 18). (B)
Platelets preincubated or not for 2 min with 20 ng of PGI2
per ml were stimulated with 100 nM ionomycin in the presence of 1 mM
CaCl2 for the indicated times. Cell lysates were split and
analyzed for the presence of RalGTP, Rap1GTP, and RasGTP, as described
for panel A. --, resting platelets.
|
|
 |
DISCUSSION |
Use of GST-RalBD as an activation-specific probe for Ral.
In
this report we demonstrate that GST-RalBD, a tagged version of the Ral
binding domain of RLIP76, binds to purified Ral loaded with a GTP
analog but not to RalGDP. We used GST-RalBD to pull down RalGTP from
cellular lysates of cells transfected with Ral mutants and showed that
the amount of Ral precipitated correlates with the levels of bound GTP.
The same method was used to monitor Ral activation in platelets, using
a monoclonal anti-RalA antibody. Although this antibody was raised to a
peptide that contains RalA-specific sequences, it may cross-react with
RalB, which is 85% identical to RalA. Due to the unavailability of
antibodies that can precipitate Ral, it is difficult to compare the Ral
activation that we observed in platelet cell lysates by this method
with the actual ratio of GTP and GDP bound to Ral. However, for Ras we
found that a similar method using GST-Raf-RBD revealed increases in
RasGTP that correlated very nicely with the increased ratio of GTP
versus GDP bound to Ras (12). In conclusion, the procedure we describe here is a fast and reliable way to qualitatively analyze increases in RalGTP.
Rapid Ca2+-mediated activation of Ral in human
platelets.
To test the assay in vivo we used human platelets,
since in these cell fragments Ral is a major GTP binding protein
(2). Indeed, when platelets are stimulated with
-thrombin, Ral is very rapidly activated. This provides the first
example of ligand-induced activation of Ral. Also, the platelet
agonists PAF and TxA2 activate Ral, suggesting that Ral
activation is mediated by a common signaling event. As we show, this
pathway involves an increase in the level of cytosolic
Ca2+, either by the mobilization from internal stores or by
the influx of Ca2+. This evidence is based on the
observation that the calcium chelator BAPTA-AM completely inhibits
-thrombin-induced activation of Ral, whereas artificial
Ca2+ mobilization with either thapsigargin or ionomycin
induces Ral activation. Recently, it has been shown that activation of
platelets by
-thrombin and other platelet agonists requires
activation of the heterotrimeric G protein Gq
(37). Gq mediates the activation of
phospholipase C-
in platelets (35, 37). This enzyme
hydrolyzes phosphatidylinositol-4,5-diphosphate, resulting in the
second messengers DAG and InsP3. InsP3 in turn
releases Ca2+ from internal stores, which may trigger the
influx of Ca2+ (26). Consistent with this
finding, ADP, which induces only a small increase in InsP3
formation and Ca2+ release (37), is a weak
activator of Ral.
How Ca
2+ subsequently activates Ral is unclear,
although several possibilities can be envisioned. First,
Ca
2+ may have a direct effect on Ral activity: RalA from
erythrocytes
can bind to calmodulin in a Ca
2+-dependent
fashion, which might influence Ral activation (
51).
Alternatively, phosphorylation by Ca
2+-dependent kinases
may regulate the activity of RalGEFs or RalGAPs,
or there might exist
Ral-specific homologs of the Ca
2+-sensitive Ras guanine
nucleotide-releasing factor (RasGRF) (
15).
Second, Ral activation may occur via a mechanism involving Ras family
members acting as upstream activators of RalGEFs (
17).
Interestingly, the pattern of Ral activation in platelets reveals
a
good correlation with the activation of Rap1 but a less clear
correlation with the activation of Ras, since (i) Ca
2+ is
necessary and sufficient for rapid activation of both Rap1
and Ral in
platelets, but not for Ras activation, and (ii)

-thrombin-induced
activation of Rap1 and Ral is not inhibited by PKC inhibition
in
platelets (Fig.
5 and reference
18), in contrast to

-thrombin-induced
activation of Ras (reference
42
and data not shown). Furthermore,
Rap1 activation and Ral activation
exhibit similar kinetics in
response to the different platelet
agonists:

-thrombin-stimulated
activation of both Rap1 and Ral is
maximal after 1 min and remains
elevated for several minutes, and the
activation of both Rap1
and Ral by PAF is transient (Fig.
1C and
reference
18). Contradicting
the idea that Rap1 may
act as an upstream activator of Ral is
the observation that a putative
activated form of Rap1, Rap1-E63,
interacted with but did not activate
RalGDS in a transient-transfection
experiment with Cos7 cells
(
48). However, Rap1 signaling in
Cos7 cells and that in
platelets could be different, for instance,
because the localization of
Rap1 and Ral in Cos7 cells may differ
from that in platelets. Recently,
it was shown that upon incorporation
in liposomes, Rap can stimulate
GDP release from Ral through RalGDS,
providing evidence that, in
principle, Rap1 can activate RalGEFs
(
24). It is also
possible that a second, Ca
2+-induced signal cooperates with
Rap1 in the activation of Ral.
The possible connection between Rap1 and
Ral does not exclude
the possibility that one of the other Ras-like
GTPases which can
interact with RalGEFs is involved in the activation
of Ral as
well (
27,
34,
48,
52).
Downstream targets of Ral signal transduction.
The only
putative target of active Ral that has been described so far is RLIP76,
which exhibits GAP activity for Cdc42. This indicates that Ral
activation may function either to downregulate the activity of Cdc42 or
to inhibit Cdc42 GAP activity, resulting in activation of Cdc42. In
turn, Cdc42 regulates cytoskeletal rearrangements, which might involve
the Cdc42 effector molecule Wiskott-Aldrich syndrome protein
(45). Mutations in this molecule lead to severe
abnormalities in the cytoskeletons of platelets (23).
The intracellular localization of the Ral proteins has led to the
speculation that Ral might be involved in exo- or endocytosis:
Ral has
been detected in endocytotic vesicles (
16) and in synaptic
vesicles (
4,
16,
36,
50) and was found to be associated
with
specialized secretory organelles, the dense granules, in
platelets
(
29). Furthermore, our results demonstrate that Ral
can
become activated by agents which can also stimulate secretion
in
platelets. For example, treatment of platelets with 0.1 to
0.5 U of

-thrombin per ml induces the fusion of dense granules
with the
plasma membrane and the open canalicular system (
33),
which
may lead to the release of ADP functioning in positive feedback.
Interestingly, there is evidence that Ca
2+ can rapidly and
strongly stimulate exocytosis in platelets and
other cells (
8,
25). PLD1, which binds to RalA, has also
been implicated in
secretion in platelets (
8,
9,
20,
25,
32). It is not clear
how PLD1 activity is regulated by Ral:
although dominant negative Ral
can inhibit Src-induced PLD activation,
the interaction between Ral and
PLD1 is independent of the activation
state of Ral (
21,
28).
Stimulation of PLD activity in platelets
has been reported to be mainly
the result of PKC activation (
30)
and therefore does not
correlate with Ral activation. It might
be that Ral is involved in
specifically targeting PLD1 to certain
membranes, where it can be
activated by other factors, such as
PKC or the small GTPases Arf and
Rho (
14).
 |
ACKNOWLEDGMENTS |
We thank our colleagues for assistance and support and Boudewijn
Burgering for critically reading the manuscript.
This work was supported by the Dutch Organization for Scientific
Research (GB-MW; NWO), The Netherlands Heart Foundation (grant 94.136),
the EC (grant BIO-4-CT96-1110), and the Dutch Cancer Society (KWF).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Stratenum,
Universiteitsweg 100, 3584 CG Utrecht, The Netherlands. Phone:
31-30-2538989. Fax: 31-30-2539035. E-mail:
J.L.Bos{at}med.ruu.nl.
 |
REFERENCES |
| 1.
|
Albright, C. F.,
B. W. Giddings,
J. Liu,
M. Vito, and R. A. Weinberg.
1993.
Characterization of a guanine nucleotide dissociation stimulator for a ras-related GTPase.
EMBO J.
12:339-347[Medline].
|
| 2.
|
Bhullar, R. P.,
P. Chardin, and R. J. Haslam.
1990.
Identification of multiple ral gene products in human platelets that account for some but not all of the platelet Gn-proteins.
FEBS Lett.
260:48-52[Medline].
|
| 3.
|
Bhullar, R. P., and H. D. Seneviratne.
1996.
Characterization of human platelet GTPase activating protein for the Ral GTP-binding protein.
Biochim. Biophys. Acta
1311:181-188[Medline].
|
| 4.
|
Bielinski, D. F.,
H. Y. Pyun,
K. Linko-Stentz,
I. G. Macara, and R. E. Fine.
1993.
Ral and Rab3a are major GTP-binding proteins of axonal rapid transport and synaptic vesicles and do not redistribute following depolarization stimulated synaptosomal exocytosis.
Biochim. Biophys. Acta
1151:246-256[Medline].
|
| 5.
|
Cantor, S. B.,
T. Urano, and L. A. Feig.
1995.
Identification and characterization of Ral-binding protein 1, a potential downstream target of Ral GTPases.
Mol. Cell. Biol.
15:4578-4584[Abstract].
|
| 6.
|
Chardin, P., and A. Tavitian.
1989.
Coding sequences of human ralA and ralB cDNAs.
Nucleic Acids Res.
17:4380[Free Full Text].
|
| 7.
|
Chardin, P., and A. Tavitian.
1986.
The Ral gene: a new Ras-related gene isolated by the use of a synthetic probe.
EMBO J.
5:2203-2208[Medline].
|
| 8.
|
Coorssen, J. R.
1996.
Phospholipase activation and secretion: evidence that PLA2, PLC, and PLD are not essential to exocytosis.
Am. J. Physiol.
270:C1153-C1163[Abstract/Free Full Text].
|
| 9.
|
Coorssen, J. R.,
H. Schmitt, and W. Almers.
1996.
Ca2+ triggers massive exocytosis in Chinese hamster ovary cells.
EMBO J.
15:3787-3791[Medline].
|
| 10.
|
D'Adamo, D. R.,
S. Novick,
J. M. Kahn,
P. Leonardi, and A. Pellicer.
1997.
Rsc: a novel oncogene with structural and functional homology with the gene family of exchange factors for Ral.
Oncogene
14:1295-1305[Medline].
|
| 11.
|
Dash, D.,
M. Aepfelbacher, and W. Siess.
1995.
The association of pp125FAK, pp60Src, CDC42Hs and Rap1B with the cytoskeleton of aggregated platelets is a reversible process regulated by calcium.
FEBS Lett.
363:231-234[Medline].
|
| 12.
|
de Rooij, J., and J. L. Bos.
1997.
Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras.
Oncogene
14:623-625[Medline].
|
| 13.
|
Emkey, R.,
S. Freedman, and L. A. Feig.
1991.
Characterization of a GTPase-activating protein for the Ras-related Ral protein.
J. Biol. Chem.
266:9703-9706[Abstract/Free Full Text].
|
| 14.
|
Exton, J. H.
1997.
New developments in phospholipase D.
J. Biol. Chem.
272:15579-15582[Free Full Text].
|
| 15.
|
Farnsworth, C. L.,
N. W. Freshney,
L. B. Rosen,
A. Ghosh,
M. E. Greenberg, and L. A. Feig.
1995.
Calcium activation of Ras mediated by neuronal exchange factor Ras-GRF.
Nature
376:524-527[Medline].
|
| 16.
|
Feig, L. A., and R. Emkey.
1993.
Ral gene products and their regulation, p. 247-258.
In
J. C. Lacal, and F. McCormick (ed.), The ras superfamily of GTPases. CRC Press, London, England.
|
| 17.
|
Feig, L. A.,
T. Urano, and S. Cantor.
1996.
Evidence for a Ras/Ral signaling cascade.
Trends Biochem. Sci.
21:438-441[Medline].
|
| 18.
|
Franke, B.,
J. W. N. Akkerman, and J. L. Bos.
1997.
Rapid Ca2+-mediated activation of Rap1 in human platelets.
EMBO J.
16:252-259[Medline].
|
| 19.
|
Frech, M.,
I. Schlichting,
A. Wittinghofer, and P. Chardin.
1990.
Guanine nucleotide binding properties of the mammalian RalA protein produced in Escherichia coli.
J. Biol. Chem.
265:6353-6359[Abstract/Free Full Text].
|
| 20.
|
Haslam, R. J., and J. R. Coorssen.
1993.
Evidence that activation of phospholipase D can mediate secretion from permeabilized platelets.
Adv. Exp. Med. Biol.
344:149-164[Medline].
|
| 21.
|
Jiang, H.,
J. Q. Luo,
T. Urano,
P. Frankel,
Z. Lu,
D. A. Foster, and L. A. Feig.
1995.
Involvement of Ral GTPase in v-Src-induced phospholipase D activation.
Nature
378:409-412[Medline].
|
| 22.
|
Jullien-Flores, V.,
O. Dorseuil,
F. Romero,
F. Letourneur,
S. Saragosti,
R. Berger,
A. Tavitian,
G. Gacon, and J. H. Camonis.
1995.
Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity.
J. Biol. Chem.
270:22473-22477[Abstract/Free Full Text].
|
| 23.
|
Kikuchi, A.,
S. D. Demo,
Z.-H. Ye,
Y.-W. Chen, and L. T. Williams.
1994.
ralGDS family members interact with the effector loop of ras p21.
Mol. Cell. Biol.
14:7483-7491[Abstract/Free Full Text].
|
| 24.
|
Kishida, S.,
S. Koyama,
K. Matsubara,
M. Kishida,
Y. Matsuura, and A. Kikuchi.
1997.
Colocalization of Ras and Ral on the membrane is required for Ras-dependent Ral activation through Ral GDP dissociation stimulator.
Oncogene
15:2899-2907[Medline].
|
| 25.
|
Knight, D. E.,
V. Niggli, and M. C. Scrutton.
1984.
Thrombin and activators of protein kinase C modulate secretory responses of permeabilised human platelets induced by Ca2+.
Eur. J. Biochem.
143:437-446[Medline].
|
| 26.
|
Kroll, M. H., and A. I. Schafer.
1989.
Biochemical mechanisms of platelet activation.
Blood
74:1181-1195[Free Full Text].
|
| 27.
|
Lopez-Barahona, M.,
X. R. Bustelo, and M. Barbacid.
1996.
The TC21 oncoprotein interacts with the Ral guanosine nucleotide dissociation factor.
Oncogene
12:463-470[Medline].
|
| 28.
|
Luo, J. Q.,
X. Liu,
S. M. Hammond,
W. C. Colley,
L. A. Feig,
M. A. Frohman,
A. J. Morris, and D. A. Foster.
1997.
RalA interacts directly with the Arf-responsive, PIP2-dependent phospholipase D1.
Biochem. Biophys. Res. Commun.
235:854-859[Medline].
|
| 29.
|
Mark, B. L.,
O. Jilkina, and R. P. Bhullar.
1996.
Association of Ral GTP-binding protein with human platelet dense granules.
Biochem. Biophys. Res. Commun.
225:40-46[Medline].
|
| 30.
|
Martinson, E. A.,
S. Scheible,
A. Greinacher, and P. Presek.
1995.
Platelet phospholipase D is activated by protein kinase C via an integrin alpha IIb beta 3-independent mechanism.
Biochem. J.
310:623-628.
|
| 31.
|
Moolenaar, W. H.,
O. Kranenburg,
F. R. Postma, and G. C. Zondag.
1997.
Lysophosphatidic acid: G-protein signalling and cellular responses.
Curr. Opin. Cell Biol.
9:168-173[Medline].
|
| 32.
|
Morgan, C. P.,
H. Sengelov,
J. Whatmore,
N. Borregaard, and S. Cockcroft.
1997.
ADP-ribosylation-factor-regulated phospholipase D activity localizes to secretory vesicles and mobilizes to the plasma membrane following N-formymethionyl-leucyl-phenylalanine stimulation of human neutrophils.
Biochem. J.
325:581-585.
|
| 33.
|
Morgenstern, E.
1995.
The formation of compound granules from different types of secretory organelles in human platelets (dense granules and alpha-granules). A cryofixation/-substitution study using serial sections.
Eur. J. Cell Biol.
68:183-190[Medline].
|
| 34.
|
Murai, H.,
M. Ikeda,
S. Kishida,
O. Ishida,
M. Okazaki-Kishida,
Y. Matsuura, and A. Kikuchi.
1997.
Characterization of Ral GDP dissociation stimulator-like (RGL) activities to regulate c-fos promoter and the GDP/GTP exchange of Ral.
J. Biol. Chem.
272:10483-10490[Abstract/Free Full Text].
|
| 35.
|
Neer, E. J.
1995.
Heterotrimeric G proteins: organizers of transmembrane signals.
Cell
80:249-257[Medline].
|
| 36.
|
Ngsee, J. K.,
L. A. Elferink, and R. H. Scheller.
1991.
A family of ras-like GTP-binding proteins expressed in electromotor neurons.
J. Biol. Chem.
266:2675-2680[Abstract/Free Full Text].
|
| 37.
|
Offermans, S.,
C. F. Toombs,
Y.-H. Hu, and M. I. Simon.
1997.
Defective platelet activation in G q-deficient mice.
Nature
389:183-186[Medline].
|
| 38.
|
Okazaki, M.,
S. Kishida,
T. Hinoi,
T. Hasegawa,
M. Tamada,
T. Kataoka, and A. Kikuchi.
1997.
Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
Oncogene
14:515-521[Medline].
|
| 39.
|
Olofsson, B.,
P. Chardin,
N. Touchot,
A. Zahraoui, and A. Tavitian.
1988.
Expression of the ras-related ralA, rho12 and rab genes in adult mouse tissues.
Oncogene
3:231-234[Medline].
|
| 40.
|
Park, S. H., and R. A. Weinberg.
1995.
A putative effector of Ral has homology to Rho/Rac GTPase activating proteins.
Oncogene
11:2349-2355[Medline].
|
| 41.
|
Polakis, P. G.,
R. F. Weber,
B. Nevins,
J. R. Didsbury,
T. Evans, and R. Snyderman.
1989.
Identification of the ral and rac1 gene products, low molecular mass GTP-binding proteins from human platelets.
J. Biol. Chem.
264:16383-16389[Abstract/Free Full Text].
|
| 42.
|
Shock, D. D.,
K. He,
D. J. Wencel, and L. V. Parise.
1997.
Ras activation in platelets after stimulation of the thrombin receptor, thromboxane A2 receptor or protein kinase C.
Biochem. J.
321:525-530.
|
| 43.
|
Siess, W.
1989.
Molecular mechanisms of platelet activation.
Physiol. Rev.
69:58-178[Free Full Text].
|
| 44.
|
Spaargaren, M., and J. R. Bischoff.
1994.
Identification of the guanine nucleotide dissociation stimulator for Ral as a putative effector molecule of R-ras, H-ras, K-ras and Rap.
Proc. Natl. Acad. Sci. USA
91:12609-12613[Abstract/Free Full Text].
|
| 45.
|
Symons, M.,
J. M. Derry,
B. Karlak,
S. Jiang,
V. Lemahieu,
F. McCormick,
U. Francke, and A. Abo.
1996.
Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization.
Cell
84:723-734[Medline].
|
| 46.
|
Torti, M., and E. G. Lapetina.
1994.
Structure and function of rap proteins in human platelets.
Thromb. Haemostasis
71:533-543[Medline].
|
| 47.
|
Toullec, D.,
P. Pianetti,
H. Coste,
P. Bellevergue,
T. Grand-Perret,
M. Ajakane,
V. Baudet,
P. Boissin,
E. Boursier,
F. Loriolle, et al.
1991.
The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C.
J. Biol. Chem.
266:15771-15781[Abstract/Free Full Text].
|
| 48.
|
Urano, T.,
R. Emkey, and L. A. Feig.
1996.
Ral-GTPases mediate a distinct downstream signaling pathway from Ras that facilitates transformation.
EMBO J.
15:810-816[Medline].
|
| 49.
|
van Willigen, G.,
I. Hers,
G. G. Gorter, and J. W. N. Akkerman.
1996.
Exposure of ligand-binding sites on platelet integrin alphaII-beta3 by phosphorylation of the beta3 subunit.
Biochem. J.
314:769-779.
|
| 50.
|
Volknandt, W.,
J. Pevsner,
L. A. Elferink, and R. H. Scheller.
1993.
Association of three small GTP-binding proteins with cholinergic synaptic vesicles.
FEBS Lett.
317:53-56[Medline].
|
| 51.
|
Wang, K. L.,
M. T. Khan, and B. D. Roufogalis.
1997.
Identification and characterization of a calmodulin-binding domain in Ral-A, a Ras-related GTP-binding protein purified from human erythrocyte membrane.
J. Biol. Chem.
272:16002-16009[Abstract/Free Full Text].
|
| 52.
|
Wolthuis, R. M. F.,
B. Bauer,
L. J. van't Veer,
A. M. M. de Vries-Smits,
R. H. Cool,
M. Spaargaren,
A. Wittinghofer,
B. M. T. Burgering, and J. L. Bos.
1996.
RalGDS-like factor (Rlf) is a novel Ras and Rap 1A-associating protein.
Oncogene
13:353-362[Medline].
|
| 53.
|
Wolthuis, R. M. F.,
N. D. de Ruiter,
R. H. Cool, and J. L. Bos.
1997.
Stimulation of gene induction and cell growth by the Ras effector Rlf.
EMBO J.
22:6748-6761.
|
Mol Cell Biol, May 1998, p. 2486-2491, Vol. 18, No. 5
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Rondaij, M. G., Bierings, R., van Agtmaal, E. L., Gijzen, K. A., Sellink, E., Kragt, A., Ferguson, S. S. G., Mertens, K., Hannah, M. J., van Mourik, J. A., Fernandez-Borja, M., Voorberg, J.
(2008). Guanine exchange factor RalGDS mediates exocytosis of Weibel-Palade bodies from endothelial cells. Blood
112: 56-63
[Abstract]
[Full Text]
-
Karim, Z. A., Choi, W., Whiteheart, S. W.
(2008). Primary Platelet Signaling Cascades and Integrin-mediated Signaling Control ADP-ribosylation Factor (Arf) 6-GTP Levels during Platelet Activation and Aggregation. J. Biol. Chem.
283: 11995-12003
[Abstract]
[Full Text]
-
de Gorter, D. J. J., Reijmers, R. M., Beuling, E. A., Naber, H. P. H., Kuil, A., Kersten, M. J., Pals, S. T., Spaargaren, M.
(2008). The small GTPase Ral mediates SDF-1-induced migration of B cells and multiple myeloma cells. Blood
111: 3364-3372
[Abstract]
[Full Text]
-
Kawato, M., Shirakawa, R., Kondo, H., Higashi, T., Ikeda, T., Okawa, K., Fukai, S., Nureki, O., Kita, T., Horiuchi, H.
(2008). Regulation of Platelet Dense Granule Secretion by the Ral GTPase-Exocyst Pathway. J. Biol. Chem.
283: 166-174
[Abstract]
[Full Text]
-
de Gorter, D. J. J., Vos, J. C. M., Pals, S. T., Spaargaren, M.
(2007). The B Cell Antigen Receptor Controls AP-1 and NFAT Activity through Ras-Mediated Activation of Ral. J. Immunol.
178: 1405-1414
[Abstract]
[Full Text]
-
Yoshizaki, H., Mochizuki, N., Gotoh, Y., Matsuda, M.
(2007). Akt-PDK1 Complex Mediates Epidermal Growth Factor-induced Membrane Protrusion through Ral Activation. Mol. Biol. Cell
18: 119-128
[Abstract]
[Full Text]
-
Goldberg, L., Kloog, Y.
(2006). A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks Phosphatidylinositol 3-Kinase-Dependent Glioblastoma Cell Migration. Cancer Res.
66: 11709-11717
[Abstract]
[Full Text]
-
Mazzochi, C., Benos, D. J., Smith, P. R.
(2006). Interaction of epithelial ion channels with the actin-based cytoskeleton. Am. J. Physiol. Renal Physiol.
291: F1113-F1122
[Abstract]
[Full Text]
-
Lad, Y., McHugh, B., Hodkinson, P. S., MacKinnon, A. C., Haslett, C., Ginsberg, M. H., Sethi, T.
(2006). Phospholipase C{epsilon} Suppresses Integrin Activation. J. Biol. Chem.
281: 29501-29512
[Abstract]
[Full Text]
-
Kondo, H., Shirakawa, R., Higashi, T., Kawato, M., Fukuda, M., Kita, T., Horiuchi, H.
(2006). Constitutive GDP/GTP Exchange and Secretion-dependent GTP Hydrolysis Activity for Rab27 in Platelets. J. Biol. Chem.
281: 28657-28665
[Abstract]
[Full Text]
-
Omidvar, N., Pearn, L., Burnett, A. K., Darley, R. L.
(2006). Ral Is both Necessary and Sufficient for the Inhibition of Myeloid Differentiation Mediated by Ras. Mol. Cell. Biol.
26: 3966-3975
[Abstract]
[Full Text]
-
Choi, W., Karim, Z. A., Whiteheart, S. W.
(2006). Arf6 plays an early role in platelet activation by collagen and convulxin. Blood
107: 3145-3152
[Abstract]
[Full Text]
-
Rosse, C., Hatzoglou, A., Parrini, M.-C., White, M. A., Chavrier, P., Camonis, J.
(2006). RalB Mobilizes the Exocyst To Drive Cell Migration. Mol. Cell. Biol.
26: 727-734
[Abstract]
[Full Text]
-
Matallanas, D., Sanz-Moreno, V., Arozarena, I., Calvo, F., Agudo-Ibanez, L., Santos, E., Berciano, M. T., Crespo, P.
(2006). Distinct Utilization of Effectors and Biological Outcomes Resulting from Site-Specific Ras Activation: Ras Functions in Lipid Rafts and Golgi Complex Are Dispensable for Proliferation and Transformation. Mol. Cell. Biol.
26: 100-116
[Abstract]
[Full Text]
-
Qin, Y., Zhu, Y., Baumgart, J. P., Stornetta, R. L., Seidenman, K., Mack, V., van Aelst, L., Zhu, J. J.
(2005). State-dependent Ras signaling and AMPA receptor trafficking. Genes Dev.
19: 2000-2015
[Abstract]
[Full Text]
-
Vitale, N., Mawet, J., Camonis, J., Regazzi, R., Bader, M.-F., Chasserot-Golaz, S.
(2005). The Small GTPase RalA Controls Exocytosis of Large Dense Core Secretory Granules by Interacting with ARF6-dependent Phospholipase D1. J. Biol. Chem.
280: 29921-29928
[Abstract]
[Full Text]
-
Wu, J.-C., Chen, T.-Y., Yu, C.-T. R., Tsai, S.-J., Hsu, J.-M., Tang, M.-J., Chou, C.-K., Lin, W.-J., Yuan, C.-J., Huang, C.-Y. F.
(2005). Identification of V23RalA-Ser194 as a Critical Mediator for Aurora-A-induced Cellular Motility and Transformation by Small Pool Expression Screening. J. Biol. Chem.
280: 9013-9022
[Abstract]
[Full Text]
-
Rondaij, M. G., Sellink, E., Gijzen, K. A., ten Klooster, J. P., Hordijk, P. L., van Mourik, J. A., Voorberg, J.
(2004). Small GTP-Binding Protein Ral Is Involved in cAMP-Mediated Release of von Willebrand Factor From Endothelial Cells. Arterioscler. Thromb. Vasc. Bio.
24: 1315-1320
[Abstract]
[Full Text]
-
Takaya, A., Ohba, Y., Kurokawa, K., Matsuda, M.
(2004). RalA Activation at Nascent Lamellipodia of Epidermal Growth Factor-stimulated Cos7 Cells and Migrating Madin-Darby Canine Kidney Cells. Mol. Biol. Cell
15: 2549-2557
[Abstract]
[Full Text]
-
Lebreton, S., Boissel, L., Moreau, J.
(2003). Control of embryonic Xenopus morphogenesis by a Ral-GDS/Xral branch of the Ras signalling pathway. J. Cell Sci.
116: 4651-4662
[Abstract]
[Full Text]
-
LANIGAN, T. M., LIU, A., HUANG, Y. Z., MEI, L., MARGOLIS, B., GUAN, K.-L.
(2003). Human homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf. FASEB J.
17: 2048-2060
[Abstract]
[Full Text]
-
Ling, L., Zhu, T., Lobie, P. E.
(2003). Src-CrkII-C3G-dependent Activation of Rap1 Switches Growth Hormone-stimulated p44/42 MAP Kinase and JNK/SAPK Activities. J. Biol. Chem.
278: 27301-27311
[Abstract]
[Full Text]
-
de Bruyn, K. M. T., Zwartkruis, F. J. T., de Rooij, J., Akkerman, J.-W. N., Bos, J. L.
(2003). The Small GTPase Rap1 Is Activated by Turbulence and Is Involved in Integrin {alpha}IIb{beta}3-mediated Cell Adhesion in Human Megakaryocytes. J. Biol. Chem.
278: 22412-22417
[Abstract]
[Full Text]
-
Hu, Y., Mivechi, N. F.
(2003). HSF-1 Interacts with Ral-binding Protein 1 in a Stress-responsive, Multiprotein Complex with HSP90 in Vivo. J. Biol. Chem.
278: 17299-17306
[Abstract]
[Full Text]
-
Mirey, G., Balakireva, M., L'Hoste, S., Rosse, C., Voegeling, S., Camonis, J.
(2003). A Ral Guanine Exchange Factor-Ral Pathway Is Conserved in Drosophila melanogaster and Sheds New Light on the Connectivity of the Ral, Ras, and Rap Pathways. Mol. Cell. Biol.
23: 1112-1124
[Abstract]
[Full Text]
-
Xu, L., Frankel, P., Jackson, D., Rotunda, T., Boshans, R. L., D'Souza-Schorey, C., Foster, D. A.
(2003). Elevated Phospholipase D Activity in H-Ras- but Not K-Ras-Transformed Cells by the Synergistic Action of RalA and ARF6. Mol. Cell. Biol.
23: 645-654
[Abstract]
[Full Text]
-
Singh, L., Gao, Q., Kumar, A., Gotoh, T., Wazer, D. E., Band, H., Feig, L. A., Band, V.
(2002). The High-Risk Human Papillomavirus Type 16 E6 Counters the GAP Function of E6TP1 toward Small Rap G Proteins. J. Virol.
77: 1614-1620
[Abstract]
[Full Text]
-
Zhu, T., Ling, L., Lobie, P. E.
(2002). Identification of a JAK2-independent Pathway Regulating Growth Hormone (GH)-stimulated p44/42 Mitogen-activated Protein Kinase Activity. GH ACTIVATION OF Ral AND PHOSPHOLIPASE D IS Src-DEPENDENT. J. Biol. Chem.
277: 45592-45603
[Abstract]
[Full Text]
-
Clough, R. R., Sidhu, R. S., Bhullar, R. P.
(2002). Calmodulin Binds RalA and RalB and Is Required for the Thrombin-induced Activation of Ral in Human Platelets. J. Biol. Chem.
277: 28972-28980
[Abstract]
[Full Text]
-
Prevost, N., Woulfe, D., Tanaka, T., Brass, L. F.
(2002). Interactions between Eph kinases and ephrins provide a mechanism to support platelet aggregation once cell-to-cell contact has occurred. Proc. Natl. Acad. Sci. USA
99: 9219-9224
[Abstract]
[Full Text]
-
Bertoni, A., Tadokoro, S., Eto, K., Pampori, N., Parise, L. V., White, G. C., Shattil, S. J.
(2002). Relationships between Rap1b, Affinity Modulation of Integrin alpha IIbbeta 3, and the Actin Cytoskeleton. J. Biol. Chem.
277: 25715-25721
[Abstract]
[Full Text]
-
Matsuzaki, T., Hanai, S., Kishi, H., Liu, Z., Bao, Y., Kikuchi, A., Tsuchida, K., Sugino, H.
(2002). Regulation of Endocytosis of Activin Type II Receptors by a Novel PDZ Protein through Ral/Ral-binding Protein 1-dependent Pathway. J. Biol. Chem.
277: 19008-19018
[Abstract]
[Full Text]
-
Post, G. R., Swiderski, C., Waldrop, B. A., Salty, L., Glembotski, C. C., Wolthuis, R. M. F., Mochizuki, N.
(2002). Guanine Nucleotide Exchange Factor-like Factor (Rlf) Induces Gene Expression and Potentiates alpha 1-Adrenergic Receptor-induced Transcriptional Responses in Neonatal Rat Ventricular Myocytes. J. Biol. Chem.
277: 15286-15292
[Abstract]
[Full Text]
-
Ward, Y., Wang, W., Woodhouse, E., Linnoila, I., Liotta, L., Kelly, K.
(2001). Signal Pathways Which Promote Invasion and Metastasis: Critical and Distinct Contributions of Extracellular Signal-Regulated Kinase and Ral-Specific Guanine Exchange Factor Pathways. Mol. Cell. Biol.
21: 5958-5969
[Abstract]
[Full Text]
-
Rosário, M., Paterson, H. F., Marshall, C. J.
(2001). Activation of the Ral and Phosphatidylinositol 3' Kinase Signaling Pathways by the Ras-Related Protein TC21. Mol. Cell. Biol.
21: 3750-3762
[Abstract]
[Full Text]
-
de Leeuw, H. P. J. C., Fernandez-Borja, M., Reits, E. A. J., Romani de Wit, T., Wijers-Koster, P. M., Hordijk, P. L., Neefjes, J., van Mourik, J. A., Voorberg, J.
(2001). Small GTP-Binding Protein Ral Modulates Regulated Exocytosis of von Willebrand Factor by Endothelial Cells. Arterioscler. Thromb. Vasc. Bio.
21: 899-904
[Abstract]
[Full Text]
-
Garcia, J., de Gunzburg, J., Eychène, A., Gisselbrecht, S., Porteu, F.
(2001). Thrombopoietin-Mediated Sustained Activation of Extracellular Signal-Regulated Kinase in UT7-Mpl Cells Requires Both Ras-Raf-1- and Rap1-B-Raf-Dependent Pathways. Mol. Cell. Biol.
21: 2659-2670
[Abstract]
[Full Text]
-
Peyssonnaux, C., Provot, S., Felder-Schmittbuhl, M. P., Calothy, G., Eychène, A.
(2000). Induction of Postmitotic Neuroretina Cell Proliferation by Distinct Ras Downstream Signaling Pathways. Mol. Cell. Biol.
20: 7068-7079
[Abstract]
[Full Text]
-
Xing, L., Ge, C., Zeltser, R., Maskevitch, G., Mayer, B. J., Alexandropoulos, K.
(2000). c-Src Signaling Induced by the Adapters Sin and Cas Is Mediated by Rap1 GTPase. Mol. Cell. Biol.
20: 7363-7377
[Abstract]
[Full Text]
-
Suzuki, J., Yamazaki, Y., Guang, L., Kaziro, Y., Koide, H.
(2000). Involvement of Ras and Ral in Chemotactic Migration of Skeletal Myoblasts. Mol. Cell. Biol.
20: 4658-4665
[Abstract]
[Full Text]
-
Franke, B., van Triest, M., de Bruijn, K. M. T., van Willigen, G., Nieuwenhuis, H. K., Negrier, C., Akkerman, J.-W. N., Bos, J. L.
(2000). Sequential Regulation of the Small GTPase Rap1 in Human Platelets. Mol. Cell. Biol.
20: 779-785
[Abstract]
[Full Text]
-
Lu, Z., Hornia, A., Joseph, T., Sukezane, T., Frankel, P., Zhong, M., Bychenok, S., Xu, L., Feig, L. A., Foster, D. A.
(2000). Phospholipase D and RalA Cooperate with the Epidermal Growth Factor Receptor To Transform 3Y1 Rat Fibroblasts. Mol. Cell. Biol.
20: 462-467
[Abstract]
[Full Text]
-
Jullien-Flores, V, Mahe, Y, Mirey, G, Leprince, C, Meunier-Bisceuil, B, Sorkin, A, Camonis, J.
(2000). RLIP76, an effector of the GTPase Ral, interacts with the AP2 complex: involvement of the Ral pathway in receptor endocytosis. J. Cell Sci.
113: 2837-2844
[Abstract]
-
Liao, Y., Kariya, K.-i., Hu, C.-D., Shibatohge, M., Goshima, M., Okada, T., Watari, Y., Gao, X., Jin, T.-G., Yamawaki-Kataoka, Y., Kataoka, T.
(1999). RA-GEF, a Novel Rap1A Guanine Nucleotide Exchange Factor Containing a Ras/Rap1A-associating Domain, Is Conserved between Nematode and Humans. J. Biol. Chem.
274: 37815-37820
[Abstract]
[Full Text]
-
de Rooij, J., Boenink, N. M., van Triest, M., Cool, R. H., Wittinghofer, A., Bos, J. L.
(1999). PDZ-GEF1, a Guanine Nucleotide Exchange Factor Specific for Rap1 and Rap2. J. Biol. Chem.
274: 38125-38130
[Abstract]
[Full Text]
-
Vo{beta}, M., Weernink, P. A. O., Haupenthal, S., Moller, U., Cool, R. H., Bauer, B., Camonis, J. H., Jakobs, K. H., Schmidt, M.
(1999). Phospholipase D Stimulation by Receptor Tyrosine Kinases Mediated by Protein Kinase C and a Ras/Ral Signaling Cascade. J. Biol. Chem.
274: 34691-34698
[Abstract]
[Full Text]
-
Reid, T., Bathoorn, A., Ahmadian, M. R., Collard, J. G.
(1999). Identification and Characterization of hPEM-2, a Guanine Nucleotide Exchange Factor Specific for Cdc42. J. Biol. Chem.
274: 33587-33593
[Abstract]
[Full Text]
-
Osada, M., Tolkacheva, T., Li, W., Chan, T. O., Tsichlis, P. N., Saez, R., Kimmelman, A. C., Chan, A. M.-L.
(1999). Differential Roles of Akt, Rac, and Ral in R-Ras-Mediated Cellular Transformation, Adhesion, and Survival. Mol. Cell. Biol.
19: 6333-6344
[Abstract]
[Full Text]
-
M'Rabet, L., Coffer, P. J., Wolthuis, R. M. F., Zwartkruis, F., Koenderman, L., Bos, J. L.
(1999). Differential fMet-Leu-Phe- and Platelet-activating Factor-induced Signaling Toward Ral Activation in Primary Human Neutrophils. J. Biol. Chem.
274: 21847-21852
[Abstract]
[Full Text]
-
Bauer, B., Mirey, G., Vetter, I. R., Garcia-Ranea, J. A., Valencia, A., Wittinghofer, A., Camonis, J. H., Cool, R. H.
(1999). Effector Recognition by the Small GTP-binding Proteins Ras and Ral. J. Biol. Chem.
274: 17763-17770
[Abstract]
[Full Text]
-
Sethi, T., Ginsberg, M. H., Downward, J., Hughes, P. E.
(1999). The Small GTP-binding Protein R-Ras Can Influence Integrin Activation by Antagonizing a Ras/Raf-initiated Integrin Suppression Pathway. Mol. Biol. Cell
10: 1799-1809
[Abstract]
[Full Text]
-
Wang, K. L., Roufogalis, B. D.
(1999). Ca2+/Calmodulin Stimulates GTP Binding to the Ras-related Protein Ral-A. J. Biol. Chem.
274: 14525-14528
[Abstract]
[Full Text]
-
Nancy, V., Wolthuis, R. M. F., de Tand, M.-F., Janoueix-Lerosey, I., Bos, J. L., de Gunzburg, J.
(1999). Identification and Characterization of Potential Effector Molecules of the Ras-related GTPase Rap2. J. Biol. Chem.
274: 8737-8745
[Abstract]
[Full Text]
-
Goi, T., Rusanescu, G., Urano, T., Feig, L. A.
(1999). Ral-Specific Guanine Nucleotide Exchange Factor Activity Opposes Other Ras Effectors in PC12 Cells by Inhibiting Neurite Outgrowth. Mol. Cell. Biol.
19: 1731-1741
[Abstract]
[Full Text]
-
Verheijen, M. H. G., Wolthuis, R. M. F., Bos, J. L., Defize, L. H. K.
(1999). The Ras/Erk Pathway Induces Primitive Endoderm but Prevents Parietal Endoderm Differentiation of F9 Embryonal Carcinoma Cells. J. Biol. Chem.
274: 1487-1494
[Abstract]
[Full Text]
-
Hackeng, C. M., Pladet, M. W., Akkerman, J.-W. N., van Rijn, H. J. M.
(1999). Low Density Lipoprotein Phosphorylates the Focal Adhesion-associated Kinase p125FAK in Human Platelets Independent of Integrin alpha IIbbeta 3. J. Biol. Chem.
274: 384-388
[Abstract]
[Full Text]
-
M'Rabet, L., Coffer, P., Zwartkruis, F., Franke, B., Segal, A. W., Koenderman, L., Bos, J. L.
(1998). Activation of the Small GTPase Rap1 in Human Neutrophils. Blood
92: 2133-2140
[Abstract]
[Full Text]
-
Rebhun, J. F., Chen, H., Quilliam, L. A.
(2000). Identification and Characterization of a New Family of Guanine Nucleotide Exchange Factors for the Ras-related GTPase Ral. J. Biol. Chem.
275: 13406-13410
[Abstract]
[Full Text]
-
de Bruyn, K. M. T., de Rooij, J., Wolthuis, R. M. F., Rehmann, H., Wesenbeek, J., Cool, R. H., Wittinghofer, A. H., Bos, J. L.
(2000). RalGEF2, a Pleckstrin Homology Domain Containing Guanine Nucleotide Exchange Factor for Ral. J. Biol. Chem.
275: 29761-29766
[Abstract]
[Full Text]
-
Shao, H., Andres, D. A.
(2000). A Novel RalGEF-like Protein, RGL3, as a Candidate Effector for Rit and Ras. J. Biol. Chem.
275: 26914-26924
[Abstract]
[Full Text]
-
Fridman, M., Maruta, H., Gonez, J., Walker, F., Treutlein, H., Zeng, J., Burgess, A.
(2000). Point Mutants of c-Raf-1 RBD with Elevated Binding to v-Ha-Ras. J. Biol. Chem.
275: 30363-30371
[Abstract]
[Full Text]
-
Anneren, C., Reedquist, K. A., Bos, J. L., Welsh, M.
(2000). GTK, a Src-related Tyrosine Kinase, Induces Nerve Growth Factor-independent Neurite Outgrowth in PC12 Cells through Activation of the Rap1 Pathway. RELATIONSHIP TO Shb TYROSINE PHOSPHORYLATION AND ELEVATED LEVELS OF FOCAL ADHESION KINASE. J. Biol. Chem.
275: 29153-29161
[Abstract]
[Full Text]
-
Senga, T., Iwamoto, T., Kitamura, T., Miyake, Y., Hamaguchi, M.
(2001). JAK/STAT3-dependent Activation of the RalGDS/Ral Pathway in M1 Mouse Myeloid Leukemia Cells. J. Biol. Chem.
276: 32678-32681
[Abstract]
[Full Text]